Hong Kong, August 30, 2022 โ DKSH Business Unit Healthcare, a leading partner for healthcare companies seeking to grow their business in Asia and beyond, is pleased to announce DKSH Hong Kong has been granted the provision of import, storage, delivery and logistic support services to the Department of Health (DoH) of the Hong Kong Special Administrative Region Government for SINOVAC CoronaVac COVID-19 vaccine in Hong Kong.
SINOVAC CoronaVac has been one of the two key COVID-19 vaccines adopted by Hong Kong since the pandemic outbreak.
In conjunction with the core logistic capabilities, DKSH offers service assurance in four key areas: quality and compliance, reliable cold-chain capability, supply chain coverage, and secured distribution. Dedicated project teams and truck fleet will be deployed to support the distribution of CoronaVac.
DKSH cold chain facility manages various life-saving drugs and healthcare products, including SINOVACโs CoronaVac, with the required temperature specifications. To further facilitate the vaccineโs storage and delivery demand for both routine and emergencies, DKSHโs team of experts set up contingency plans and temperature control measures to ensure zero excursion under different circumstances.
In addressing the need for flexible distribution and extensive coverage of the vaccine to different vaccination centers, hospitals, and clinics, DKSH has designed designated logistic processes, fleet route map and facilitation plans to safeguard a sustainable supply of vaccines.
During an engagement session at DKSH Mapletree Distribution Center to welcome the official move-in of SINOVAC CoronaVac, Ms Cheryl Law, International Business Development Director of SINOVAC, said: โWe send our congratulations to DKSH for winning the tender. We are impressed with the operation and automation of this DC facility and strongly believe DKSH has the capability to support in combating the pandemic.โ
Fong Wai Ting, Head of Management and Vice President, Healthcare, DKSH Hong Kong & Macau, commented: โThis is a significant milestone for DKSH. We are honored to serve Hong Kongโs citizens by supporting the distribution of SINOVAC CoronaVac. This project echoes DKSHโs mission of enriching peopleโs lives and is a strong recognition of the companyโs proven capability in the cold chain management, extensive industry network, and uncompromising pursuit of quality. I would also like to take this opportunity to acknowledge our teamโs effort to make this project happen.โ
About DKSHย
DKSHโs purpose is to enrich peopleโs lives. For more than 150 years, we have been delivering growth for companies in Asia and beyond across our Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, we offer sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 33,100 specialists, generating net sales of CHF 11.1 billion in 2021. The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical devices. With around 7,290 specialists, the Business Unit generated net sales of CHF 5.6 billion in 2021. www.dksh.com/hec